Document is current
Any future updates will be listed below
-
Authors
Xu, Xiao-Qian
Li, Wei-Ming
Shi, Li-Chen
Wang, Hao
Li, Shun
Huang, Cheng
You, Hong
Jia, Ji-Dong
He, You-Wen
Kong, Yuan-Yuan https://orcid.org/0000-0002-2586-1443
-
Funding
Funding for this research was provided by:
Beijing Natural Science Foundation (7254468)
National Key Research and Development Program, China (2023YFC2306902, 2023YFC2306900)
- License Information
-
More Information
Article History
Received: 3 December 2025
Accepted: 30 June 2026
First Online: 2 July 2026
Declarations
Ethics approval and consent to participate: This is a secondary analysis based on IMbrave 150 study and GO30140 trial. The Data Use Agreement with Research Plan is approved by the Vivli platform ( ). Both trials were conducted in accordance with the International Conference on Harmonization guidelines for Good Clinical Practice and the principles of the Declaration of Helsinki. The study protocols were reviewed and approved by ethics committees at each of the participating sites. The full lists of participating sites and ethics committees can be found at and . All patients gave written informed consent for participation.
Consent for publication: Not applicable.
Competing interests: The authors declare no competing interests.
